__timestamp | AbbVie Inc. | Evotec SE |
---|---|---|
Wednesday, January 1, 2014 | 4426000000 | 60118000 |
Thursday, January 1, 2015 | 4500000000 | 89690000 |
Friday, January 1, 2016 | 5833000000 | 105953000 |
Sunday, January 1, 2017 | 7040000000 | 175062000 |
Monday, January 1, 2018 | 7718000000 | 263389000 |
Tuesday, January 1, 2019 | 7439000000 | 313546000 |
Wednesday, January 1, 2020 | 15387000000 | 375181000 |
Friday, January 1, 2021 | 17446000000 | 466491000 |
Saturday, January 1, 2022 | 17414000000 | 577383000 |
Sunday, January 1, 2023 | 20415000000 | 606375000 |
Monday, January 1, 2024 | 16904000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue for two industry players: AbbVie Inc. and Evotec SE, from 2014 to 2023. Over this period, AbbVie Inc. has seen a staggering 361% increase in its cost of revenue, peaking at approximately $20 billion in 2023. This growth reflects its aggressive expansion and investment in research and development. In contrast, Evotec SE, a smaller entity, experienced a 910% rise, reaching around $606 million in 2023. While AbbVie's costs are significantly higher, Evotec's rapid growth rate highlights its dynamic approach in the biotech sector. This comparative insight underscores the diverse strategies and financial trajectories within the pharmaceutical industry, offering a window into the operational priorities of these companies.
Cost of Revenue Trends: AbbVie Inc. vs Catalent, Inc.
Analyzing Cost of Revenue: AbbVie Inc. and ADMA Biologics, Inc.
Cost of Revenue: Key Insights for AbbVie Inc. and Geron Corporation
Cost of Revenue Trends: AbbVie Inc. vs Xencor, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Evotec SE's Expenses
Cost of Revenue Comparison: Bristol-Myers Squibb Company vs Evotec SE
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Evotec SE's Expenses
Cost of Revenue: Key Insights for Alkermes plc and Evotec SE
Amneal Pharmaceuticals, Inc. vs Evotec SE: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and Evotec SE's Expenses
Analyzing Cost of Revenue: Supernus Pharmaceuticals, Inc. and Evotec SE